Fujisawa Pharmaceutical Co., Ltd.

Gloucester Pharmaceuticals acquires rights to anticancer compound

Published in Oncology Business Week, May 16th, 2004

Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, and Fujisawa Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, announced that Gloucester has acquired from Fujisawa an exclusive worldwide license to develop and commercialize Fujisawa's novel histone deacetylase inhibitor (HDAC), known as FK228, as an anticancer agent.

FK228 (depsipeptide) is currently in phase II clinical trials for the treatment of renal cell carcinoma and hormone refractory prostate cancer. FK228 is also being studied in separate phase II clinical trials for the treatment of cutaneous T-cell lymphoma, as well as other indications by the National...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2004-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry